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Abstract. Pseudomonas aeruginosa strains were isolated and identified from secretions, internal organs 
and corpses of dogs and cats, poultry and also ostriches. The susceptibility of bacteria to antibiotics was carried 
out using broth dilution method. The MIC’s of the tested antibiotics were determined and interpreted according 
to The National Committee for Clinical Laboratory Standard. 
The efficacy of the combination between enrofloxacin and gentamicin was tested, in comparison with 
enrofloxacin and gentamicin alone. Synergy studies were interpreted by ciphering out the fractional inhibitory 
concentration (FIC). 
The results according to the FIC formula showed that combination enrofloxacin-gentamicin was synergic 
in 5 strains and additive in 2 strains, meaning a 71,43 % percentage synergism and 28,57 % addition. 
We recommend the association of enrofloxacin with gentamicin because of the advantage that emerge 
from this combination against Pseudomonas aeruginosa 
 
INTRODUCTION 
 
A phenomenal increase in antibiotic-resistant bacterial pathogens is one of the major 
problems facing medicine and science today. At the same time, the pharmaceutical industry is 
reaching a plateau in the development of agents directed at novel drug targets and most of the 
efforts in antibiotic development are aimed at improving the dosage regimens, tolerability 
and, of particular importance, improving the efficacy of existing antibiotic classes. Therefore, 
it is now critical to understand the mechanisms of bacterial resistance, to optimize the use of 
the existing antibiotics and to formulate strategies to minimize or even reverse antibiotic 
resistance in bacteria (GOOSSENS HERMAN, 2006). 
Combination therapy with antimicrobial agents can be used, as a strategy, against 
bacteria that have reduced susceptibility to single agents (HOLLANDER J.G., 1998). The 
purpose of this study was to find some association of antibacterial substances with enhanced 
activity on Pseudomonas aeruginosa strains, known as resistant to many antibiotics 
(RĂPUNTEAN GH. and RĂPUNTEAN S., 2005). 
 
MATERIAL AND METHOD 
 
Antimicrobial agents from de groups of aminoglycosides (gentamicin), and 
fluoroquinolones (enrofloxacin) were tested on Pseudomonas genus. The strains were isolated 
from auricular secretion of dogs diagnosed with supurative otitis, from internal organs (liver, 
spleen) of poultry having digestive disorders with hepatic congestion and milliary necrosis, 
also hyperplasia of the spleen, from corpses of ostriches and secretion from conjunctiva of 
cats diagnosed with conjunctivitis. 
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Routine isolation and identification methods were applied to bacterial strains. 
(RĂPUNTEAN GH. and BOLDIZSAR E., 2001). 
 The susceptibility of bacteria to antibiotics was carried out using broth dilution method 
(BOLDIZSAR and all, 2002). 
The strains grew on broth at 37°C for 18-24 hours and the inoculum was placed in each 
of the tubes. The minimal inhibitory concentration (MIC) was determined after aerobic 
incubation at 37°C for 18-24 hours and was considered the lowest antimicrobial concentration 
that produced no visible bacterial growth (NCCLS, M31-A, 1999). 
The stock solutions were prepared in sterile distilled water. Serial dilution, beginning 
with 5 µg in enrofloxacin (ENR) and 10 µg in gentamicin (G) were performed in 15 tubes for 
each antibiotic. Every tube contained 1 ml broth in a twofold dilution, comparing with the 
proximate tubes. One more tube contained no antibiotic and served as a control tube 
(KOCAZEYEK B.S. and all, 2002). 
The synergism between antibiotics was observed for this combination of two antibiotics, 
enrofloxacin and gentamicin, by preparing 15 more tubes of dilutions, using ½ of the amount 
of antibiotics, beginning with the quantity of  2,5 µg ENR + 5 µg G in the first tube, then 
making twofold dilutions as described hereinbefore.  
Fractional inhibitory concentration indices (FIC) were calculated (HOLLANDER J.G. 
and all, 1998) for all isolates for this combination. 
 
RESULTS AND DISCUSSION 
 
This paper tested the efficacy of the combination between enrofloxacin and gentamicin 
on 7 strains from Pseudomonas genus, in comparison with the efficacy of enrofloxacin and 
gentamicin alone. 
The MIC’s of the tested antibiotics were determined and interpreted according to The 
National Committee for Clinical Laboratory Standards (NCCLS, M31-T, 1999) (table 1):  
 
MIC values according to the  international standards 
 
Table 1 
MIC values (µg/ml) Antibiotic  
   S            I         R Standards for dilution susceptibility tests  
Gentamicin ≤ 4                       ≥ 8 
≤ 1                       > 4 
≤ 2                       ≥ 8 
≤ 4            8         ≥16 
Neo-Sensitab Swedish Reference Group of Antibiotics  
Neo-Sensitab Dutch CRG 
Neo-Sensitab Norwegian AFA Group 
Oxoid Manual Veterinary Pathogens – NCCLS 
Enrofloxaci
n  
≤ 1                       ≥4 
≤ 0,5/0,25            4/2 
≤ 0,5        1-2       ≥ 4 
Neo-Sensitab – NCCLS 
Neo-Sensitab Veterinary Pathogens – NCCLS 
Oxoid Manual Veterinary Pathogens – Canine and 
feline (gram-negative pathogens, Staphylococcus spp. and 
other susceptible micro-organisms) 
 
Synergy studies had been interpreted by ciphering out the fractional inhibitory 
concentration (FIC) which compares the activity of an agent in combination (agent A + agent 
B) with the activity of the antibiotic alone (agent A or agent B) according to CF Referral 
Center for Susceptibility & Synergy Studies (2003). 
The interpretation of the FIC’s values are presented in the table 2: 
 
Interpretation of the FIC’s value 
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Table 2 
FIC value Interpretation 
≤ 0,5 Synergistic 
> 0,5 – 1,0 Additive 
> 1,0 - ≤ 4 Indifferent 
> 4,0 Antagonistic or not clinically achievable 
 
The results according to the FIC formula showed that combination enrofloxacin-
gentamicin was synergic in 5 strains and additive in 2 strains, meaning a 71,43 % percentage 
synergism and 28,57 % addition (table 3).  
 
FIC values for enrofloxacin-gentamicin combination against Pseudomonas strains 
 
Table 3 
Strain no.  FIC Interpretation 
1 1 Addition  
2 0,375 Synergism 
3 0,625 Addition   
4 0,375 Synergism  
5 0,1562499 Synergism  
6 0,25 Synergism 
7 0,3125 Synergism   
 
Therefore, it is a good combination of antibiotics because the efficiency of the 
association is a better one, in comparison with every antibiotic alone, no indifference being 
observed between these two antimicrobial substances (graphic 1).  
 
 
 
Graphic 1. The appreciation of enrofloxacin-gentamicin combination for Pseudomonas strains 
 
Synergism in a lower percentage pointed out BOOTHE DAWN, in 2003, when 
fluoroquinolones with aminoglycosides were combined against some Pseudomonas 
aeruginosa strains – 30 %.  
KOCAZEYEK B.S. and all, in 2002, also noted only 10 % of synergism when they 
associated ciprofloxacin and gentamicin in order to fight against Pseudomonas aeruginosa 
strains; in that study there was a 23 % percentage of synergism for the combination 
ceftriaxone-gentamicin.  
0
50
100
% 
FIC 71,43 28,57 0
Synergism
 
 Addition
 
Indifference 
 172 
WHITE R.L. and all (1996) found out also synergism when associated cephepim and 
ceftazidime with ciprofloxacin and tobramycin, for the testing against Pseudomonas 
aeruginosa strains. 
The best results on Pseudomonas aeruginosa strains were obtained by HOLLANDER 
J.G. and all (1998) when ceftazidime and tobramycin were combined, this efficacy being 
determined through many in vitro methods. 
YU K.W. PAULINE and all, in 1983, studied the antibacterial activity of moxolactam, a 
3rd generation cephalosporin, alone and in combination with gentamicin, against some 
Pseudomonas aeruginosa strains and obtained synergism in 42,86 % – 50 % of cases, 
depending on the method that was used. 
The synergism phenomenon was noted also by MOUTON J.W., in 1999, when many 
combinations of antibiotics were used against Pseudomonas aeruginosa strains: 
aminoglycosides-quinolones, quinolones-cephalosporins, cephalosporins-aminoglycosides, 
penicillins-aminoglycosides. 
Unlike these researchers, when piperacillin and ciprofloxacin were combined against 
some Pseudomonas aeruginosa strains, HYATT J.M. and all (1995) obtained addition 
between the two antibiotics; but CHEN Y.H. and all, in 2004, observed a very low potential 
for synergism in the case of ciprofloxacin associated with other antibiotics against 
Pseudomonas aeruginosa. 
Nevertheless, ERDEM I. and all (2003) noted synergism when ciprofloxacin was 
associated with beta-lactam antibiotics (meropenem, cephepim) against some Pseudomonas 
aeruginosa strains, but in a low percentage – 20 %. 
So, as a results of this study, we recommend the association of enrofloxacin with 
gentamicin because of the advantage that emerge from this combination against Pseudomonas 
aeruginosa strains. 
 
CONCLUSIONS 
 
The efficacy of the combination between enrofloxacin and gentamicin, in comparison 
with the efficacy of enrofloxacin and gentamicin alone, was tested on 7 strains from 
Pseudomonas genus 
The MIC’s of the antibiotics were determined and interpreted according to The National 
Committee for Clinical Laboratory Standards  
Synergy studies had been interpreted by ciphering out the fractional inhibitory 
concentration (FIC) which compares the activity of an agent in combination with the activity 
of the antibiotic alone 
The results according to the FIC formula showed that combination enrofloxacin-
gentamicin was synergic in 5 strains and additive in 2 strains, meaning a 71,43 % percentage 
synergism and 28,57 % addition 
We recommend the association of enrofloxacin with gentamicin because of the 
advantage that emerge from this combination against Pseudomonas aeruginosa 
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